📢 [Press Release]@DBTIndia has approved additional funding towards clinical studies of India's 'first of its kind' mRNA-based #COVID19 #vaccine - HGCO19, developed by Gennova Biopharmaceuticals Ltd.

More info: https://t.co/KQ9FsahrsK@drharshvardhan @RenuSwarup pic.twitter.com/abwTqbH3ks

— BiotechIndia (@DBTIndia) April 13, 2021